KDR and neoplasm: Furthermore, Huang et al. showed that lower doses of anti-VEGFR2 antibody improve tumor-associated vessel perfusion and reduce tumor hypoxia more effectively than the immunoglobulin-G (IgG) control and high-dose anti-VEGFR2 treatment groups [82].